Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Actinogen Medical ( (AU:ACW) ) has issued an update.
Actinogen Medical has secured a second, non-dilutive tranche of $4.3 million in research and development tax funding from Endpoints Capital, part of a previously announced facility of up to $13.8 million backed by the company’s forecast FY26 R&D Tax Incentive rebate. The fresh capital will support the ongoing XanaMIA Phase 2b/3 Alzheimer’s disease trial, which is now fully enrolled at 35 sites in Australia and the US, the launch of its open-label extension in the current quarter, and general working capital, bolstering Actinogen’s balance sheet and extending its cash runway to mid-2026 as it approaches an interim analysis and final topline results expected in November 2026.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Its lead candidate, Xanamem (emestedastat), is an oral, once-daily 11β-HSD1 inhibitor being advanced primarily for Alzheimer’s disease, with additional work in treatment-resistant depression and potential future indications such as Fragile X syndrome and other brain disorders with significant unmet medical need.
YTD Price Performance: -18.03%
Average Trading Volume: 5,562,160
Technical Sentiment Signal: Buy
Current Market Cap: A$159.6M
Learn more about ACW stock on TipRanks’ Stock Analysis page.